David Aggen, MD, PhD

Articles by David Aggen, MD, PhD

Choosing Appropriate Patients and Dosing for Lenvatinib + Pembrolizumab in RCC

ByRobert J. Motzer, MD,David Aggen, MD, PhD,Robert S. Alter, MD,Mehmet Asim Bilen, MD,Brian I. Rini, MD

March 28th 2022

Expert insights on selecting the appropriate patients and dose for treatment with the lenvatinib plus pembrolizumab regimen in patients with renal cell carcinoma.

Patient Profile 1: Favorable-Risk RCC Treated With Lenvatinib + Pembrolizumab

ByRobert J. Motzer, MD,David Aggen, MD, PhD,Robert S. Alter, MD,Mehmet Asim Bilen, MD,Brian I. Rini, MD

March 28th 2022

Experts open their discussion on RCC by reviewing the clinical scenario of a patient with favorable-risk disease who is treated with the TKI/IO regimen of lenvatinib and pembrolizumab.